Scarica l'app Stockscreener
8.97
9.93%
0.81
Dopo l'orario di chiusura:
9.06
0.09
+1.00%
Precedente Chiudi:
$8.16
Aprire:
$8.3
Volume 24 ore:
503.24K
Relative Volume:
0.56
Capitalizzazione di mercato:
$203.29M
Reddito:
$146.07M
Utile/perdita netta:
$-196.04M
Rapporto P/E:
-0.5397
EPS:
-16.621
Flusso di cassa netto:
$-75.37M
1 W Prestazione:
+20.08%
1M Prestazione:
+3.58%
6M Prestazione:
+61.62%
1 anno Prestazione:
+95.42%
Intervallo 1D:
$8.22
$9.055
Intervallo di 1 settimana:
$7.38
$9.055
Portata 52W:
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
8.97 | 184.93M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Rodman & Renshaw | Buy |
| 2026-02-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Ripresa | H.C. Wainwright | Buy |
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm (KPTI) director Christy Oliger receives 15,508 RSU equity award - Stock Titan
Karyopharm (KPTI) director awarded 15,508 RSUs vesting in 2027 - Stock Titan
Chen Schor of Karyopharm (KPTI) receives 15,508 RSU award - Stock Titan
Karyopharm Therapeutics (KPTI) director receives 15,508 RSUs in equity award - Stock Titan
Karyopharm (KPTI) director receives 15,508 RSU equity award vesting in 2027 - Stock Titan
Karyopharm (NASDAQ: KPTI) director gets 15,508 RSUs vesting in 2027 - Stock Titan
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts - Yahoo Finance
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus - Yahoo Finance
KPTI PE Ratio & Valuation, Is KPTI Overvalued - Intellectia AI
KPTI Stock Price, Quote & Chart | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026 - MSN
KPTI Technical Analysis | Trend, Signals & Chart Patterns | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm (KPTI) Leans on SENTRY in Pivotal Call - TipRanks
Earnings call transcript: Karyopharm Q1 2026 results disappoint, stock drops By Investing.com - Investing.com Australia
Earnings call transcript: Karyopharm Q1 2026 results disappoint, stock drops - Investing.com UK
Karyopharm Therapeutics (KPTI) price target increased by 13.33% to 13.87 - MSN
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
Karyopharm Therapeutics Inc.Common Stock (NQ: KPTI - FinancialContent
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI) - The Globe and Mail
Opaleye Management Inc. Reduces Stake in Karyopharm Therapeutics Inc. - GuruFocus
Ikarian Capital (KPTI) files joint 13G showing sub‑5% holding - Stock Titan
Karyopharm Therapeutics CAO Kristin Abate sells $503 in stock By Investing.com - Investing.com South Africa
Karyopharm Therapeutics CAO Kristin Abate sells $503 in stock - Investing.com
Karyopharm (KPTI) EVP nets PSUs, then small tax-driven share sale - Stock Titan
[Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity - Stock Titan
Karyopharm (KPTI) EVP earns PSU shares, sells 324 to cover taxes - Stock Titan
Karyopharm (KPTI) CAO reports PSU vesting and small pre-planned tax sale - Stock Titan
Karyopharm (KPTI) CEO logs PSU vesting and automatic tax-related share sale - Stock Titan
Karyopharm (KPTI) EVP sale covers tax on earned PSU award - Stock Titan
Karyopharm (KPTI) Schedule 13G: Acorn entities and Anders Hove report 1.52M shares - Stock Titan
RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2026 Earnings Call Transcript - Insider Monkey
[EFFECT] Karyopharm Therapeutics Inc. SEC Filing - Stock Titan
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
Karyopharm Therapeutics 1Q Loss/Shr $1.24 >KPTI - Moomoo
Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Karyopharm Therapeutics Inc (KPTI) Q1 2026 Earnings Call Highlig - GuruFocus
Karyopharm Earnings Call: Trial Wins, Cash Questions - TipRanks
Earnings Call Summary | Karyopharm Therapeutics(KPTI.US) Q1 2026 Earnings Conference - 富途牛牛
Karyopharm Therapeutics Inc (KPTI) Stock Price, Quote, News & History - Benzinga
KPTI Projects 2026 Revenue Between $130M and $150M - GuruFocus
Karyopharm Therapeutics Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Karyopharm Therapeutics (KPTI) Reports Strong Q1 Earnings, Beats Expectations - GuruFocus
Affinity Asset Advisors reports 2.07M shares in Karyopharm (KPTI) - Stock Titan
Karyopharm Therapeutics Inc. Q1 2026 Financial Results and SEC 10-Q Filing Highlights - Minichart
Karyopharm Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Karyopharm (KPTI) Q1 2026 Earnings Transcript - AOL.com
Karyopharm Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Karyopharm Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Karyopharm Therapeutics Reports Q1 2026 Results, Advances Selinexor Phase 3 Trials in Myelofibrosis and Endometrial Cancer - Minichart
Is Karyopharm Therapeutics (KPTI) Overvalued After Q1 2026 Earni - GuruFocus
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):